#1 Clinical Trials Search in Europe

Gemcitabine Hydrochloride

Gemcitabine Hydrochloride, also known as Gemzar, is a chemotherapy drug that has shown promise in treating various types of cancer. This article explores recent clinical trials investigating the use of Gemcitabine Hydrochloride alone or in combination with other drugs for different cancer types, including lung, pancreatic, ovarian, and endometrial cancers. These trials aim to improve treatment outcomes and find more effective ways to combat cancer.

Table of Contents

What is Gemcitabine Hydrochloride?

Gemcitabine Hydrochloride, also known by its brand name Gemzar, is a chemotherapy drug used to treat various types of cancer[1]. It belongs to a class of medications called antimetabolites, which work by interfering with the growth of cancer cells[2]. Gemcitabine is sometimes referred to by other names, including:

  • dFdCyd
  • Difluorodeoxycytidine Hydrochloride
  • LY-188011

These alternative names may be used by healthcare professionals or in scientific literature, but patients will most commonly hear it called Gemcitabine or Gemzar[3].

How Does Gemcitabine Work?

Gemcitabine works by stopping the growth of cancer cells in several ways[2]:

  • Blocking cell division: It interferes with the process of cell division, preventing cancer cells from multiplying.
  • Inducing cell death: Gemcitabine can trigger a process called apoptosis, which is programmed cell death, in cancer cells.
  • Inhibiting DNA synthesis: The drug blocks the production of new DNA, which is essential for cell growth and division.

By targeting these cellular processes, Gemcitabine can slow down or stop the growth of tumors and potentially shrink them[4].

What Conditions Does Gemcitabine Treat?

Gemcitabine is used to treat several types of cancer, including:

  • Pancreatic cancer: It is commonly used in the treatment of pancreatic adenocarcinoma, both in early stages and advanced disease[3].
  • Non-small cell lung cancer (NSCLC): Gemcitabine is often used in combination with other drugs to treat advanced stages of NSCLC[1].
  • Bladder cancer: It can be used as part of a chemotherapy regimen for muscle-invasive bladder cancer[5].
  • Ovarian cancer: Some treatment protocols include Gemcitabine for ovarian cancer.
  • Breast cancer: In certain cases, it may be used as part of breast cancer treatment.
  • Pediatric solid tumors: Research is ongoing to evaluate its effectiveness in treating various childhood cancers[2].

How is Gemcitabine Administered?

Gemcitabine is typically administered in the following ways:

  • Intravenous (IV) infusion: The most common method is through an IV infusion, which means the drug is given directly into a vein. This is usually done over a period of 30 minutes to an hour[1].
  • Dosing schedule: The exact schedule can vary, but a common regimen is weekly administration for 2 or 3 weeks, followed by a week of rest. This cycle is then repeated[3].
  • Combination therapy: Gemcitabine is often used in combination with other chemotherapy drugs or treatments like radiation therapy, depending on the type and stage of cancer[4].

The dosage and schedule will be determined by your oncologist based on factors such as your type of cancer, overall health, and how well you tolerate the treatment.

Potential Side Effects

Like all chemotherapy drugs, Gemcitabine can cause side effects. Some common side effects may include:

  • Fatigue: Feeling very tired is a common side effect of many cancer treatments.
  • Nausea and vomiting: These can often be managed with anti-nausea medications.
  • Low blood cell counts: This can increase the risk of infection, anemia, and bleeding.
  • Skin rash: Some patients may experience skin irritation or rashes.
  • Flu-like symptoms: Fever, chills, and body aches may occur, especially after the first few treatments.
  • Loss of appetite: This can lead to weight loss in some patients.

Your healthcare team will monitor you closely for these and other potential side effects, and can provide treatments to help manage them[1][3].

Ongoing Research and Clinical Trials

Researchers continue to study Gemcitabine to find new ways to use it effectively and to improve outcomes for patients. Some areas of ongoing research include:

  • Combination therapies: Studies are looking at combining Gemcitabine with other drugs to enhance its effectiveness. For example, a trial is investigating the combination of Gemcitabine with nab-paclitaxel (Abraxane) and radiation therapy in pancreatic cancer[3].
  • New delivery methods: Researchers are exploring different ways to administer Gemcitabine, such as an oral formulation, which could make treatment more convenient for patients[6].
  • Targeted therapies: Studies are looking at how Gemcitabine can be used alongside newer targeted therapies to improve treatment outcomes.
  • Pediatric cancers: Clinical trials are investigating the use of Gemcitabine in children with various types of solid tumors[2].

These ongoing studies aim to improve the effectiveness of Gemcitabine, reduce its side effects, and expand its use to benefit more patients with different types of cancer.

Cancer Type Trial Phase Combination Therapy Key Outcomes Measured
Non-small cell lung cancer Phase II Pemetrexed disodium Response rates, progression-free survival, overall survival
Pancreatic cancer Phase II ZN-c3 (WEE1 inhibitor) 6-month progression-free survival rate, overall survival
Ovarian, fallopian tube, primary peritoneal cancer Phase II ATR kinase inhibitor M6620 Progression-free survival, overall response rate, safety profile
Endometrial cancer Phase II None (single-agent) Objective tumor response rate, toxicity
Various solid tumors Phase 0/I None (testing oral formulation) Pharmacokinetics, safety, tolerability

FAQ

  • What is Gemcitabine Hydrochloride? Gemcitabine Hydrochloride, also known as Gemzar, is a chemotherapy drug used to treat various types of cancer. It works by stopping the growth of cancer cells, either by killing them or by stopping them from dividing.
  • What types of cancer are being studied with Gemcitabine Hydrochloride? Clinical trials are exploring the use of Gemcitabine Hydrochloride in several cancer types, including non-small cell lung cancer, pancreatic cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and endometrial cancer.
  • How is Gemcitabine Hydrochloride administered? Gemcitabine Hydrochloride is typically given intravenously (IV) over 30 minutes. The dosing schedule can vary depending on the specific trial and cancer type, but it's often given on days 1 and 8 of a 21-day cycle.
  • Are there any new formulations of Gemcitabine being studied? Yes, some trials are investigating an oral formulation of Gemcitabine Hydrochloride. This new form is being tested to see if it can be as effective as the intravenous version while potentially offering more convenience for patients.
  • What are some potential side effects of Gemcitabine Hydrochloride? While specific side effects can vary, common side effects of chemotherapy drugs like Gemcitabine Hydrochloride may include fatigue, nausea, decreased blood cell counts, and increased risk of infections. The clinical trials are closely monitoring patients for any adverse effects to ensure safety.

Ongoing Clinical Trials on Gemcitabine Hydrochloride

  • Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Denmark Finland France +9

  • Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +9

  • Study of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Italy The Netherlands +2

  • Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +7

  • A study comparing erdafitinib delivery system to chemotherapy for patients with high-risk non-muscle-invasive bladder cancer who received BCG treatment

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Greece Italy The Netherlands +1

  • Study of nadofaragene firadenovec alone or with gemcitabine, docetaxel or pembrolizumab in adults with non-muscle invasive bladder cancer who did not respond to BCG therapy

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Poland Spain

  • Study of drug combination therapy after surgery in patients with resectable pancreatic ductal adenocarcinoma using lab-grown mini-tumors to guide treatment selection

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Czechia Denmark Finland France Germany +7

  • Study Comparing Rinatabart Sesutecan with Other Treatments for Patients with Platinum-Resistant Ovarian Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +6

  • Study of sotorasib with chemotherapy combination for adult patients with advanced pancreatic cancer who have KRAS p.

    Recruiting

    1 1 1
    Investigated drugs:
    France Spain

Glossary

  • Gemcitabine Hydrochloride: A chemotherapy drug used to treat various types of cancer. It works by interfering with the growth of cancer cells and stopping them from spreading in the body.
  • Clinical trial: A research study that tests how well new medical approaches work in people. These studies test new methods of screening, prevention, diagnosis, or treatment of a disease.
  • Intravenous (IV): A way of giving medication or fluids through a needle or tube inserted directly into a vein.
  • Chemotherapy: A type of cancer treatment that uses drugs to destroy cancer cells.
  • Non-small cell lung cancer: A type of lung cancer that is the most common form of the disease, accounting for about 80-85% of all cases.
  • Pancreatic cancer: A cancer that starts in the pancreas, an organ located behind the stomach that helps with digestion and regulating blood sugar.
  • Ovarian cancer: A type of cancer that begins in the ovaries, which are part of the female reproductive system.
  • Endometrial cancer: A type of cancer that begins in the lining of the uterus (endometrium).
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall survival (OS): The length of time from either the date of diagnosis or the start of treatment for a disease that patients are still alive.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.

References

  1. https://clinicaltrials.gov/study/NCT00407550
  2. https://clinicaltrials.gov/study/NCT00005577
  3. https://clinicaltrials.gov/study/NCT01921751
  4. https://clinicaltrials.gov/study/NCT00842660
  5. https://clinicaltrials.gov/study/NCT03061630
  6. https://clinicaltrials.gov/study/NCT01678690